First US Fosamax case on jaw damage claims ends in mistrial
This article was originally published in Scrip
Executive Summary
A US judge has declared a mistrial in the first federal case to come before a jury over claims that Merck & Co did not adequately warn about a link between its oral bisphosphonate Fosamax (alendronate) and osteonecrosis of the jaw (ONJ).